Tauklarify (florquinitau F 18 injection) is a brain PET tracer that binds tau tangles, twisted tau deposits tied to Alzheimer's disease. For adults with cognitive impairment being evaluated for Alzheimer's, useful clinician questions cover need, referral site, coverage, radiation, medicines, and nursing precautions. Lantheus announced FDA approval on Aug.
14, 2026, for use in adults with cognitive impairment being evaluated for Alzheimer's to identify tau tangle pathology, according to the Lantheus approval notice. The tracer was formerly called MK-6240. It is used with PET imaging, not as a standalone diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does tau imaging add?
- How well do readers agree on scan results?
- What are the key limits?
- What should patients ask before referral?
What does tau imaging add?
Tau tangles are a separate Alzheimer's signal from amyloid plaques. The Society of Nuclear Medicine and Molecular Imaging describes Tauklarify as the second FDA-approved tau PET tracer alongside flortaucipir, adding information that complements amyloid PET during cognitive-impairment evaluation, according to the Society's 2026 tracer summary.
The agent can detect tangles isolated to the medial temporal lobe. That matters because early disease may show signal there first. Ask whether your history, exam, memory testing, amyloid result, or blood biomarker leaves a staging question that tau distribution would change.
How well do readers agree on scan results?
Approval rested on two blinded-read studies with five readers. NeurologyLive reported positive agreement of 68%-88%, negative agreement of 93%-99%, and strong inter-reader agreement, with Fleiss kappa values of 0.92 and 0.86, according to the NeurologyLive approval report.
Negative reads were more consistent than positive reads. Ask how the reading center handles uncertain uptake. Also ask whether another test will confirm the result before treatment or trial decisions.
What are the key limits?
A positive or negative scan alone neither confirms nor excludes tau pathology. Safety and effectiveness are not established for non-Alzheimer's tauopathies, so other brain diseases with tau may not be assessed correctly.
That creates misdiagnosis risk when symptoms overlap. Ask what diagnosis remains possible if tau PET is negative. Ask what other causes of memory loss are still being considered.
What should patients ask before referral?
Ask whether tau PET is needed beyond amyloid PET or blood tests. Ask where referral imaging is offered and whether insurance covers it, since broader commercial availability was still being assessed after approval.
Also review radiation and medicine precautions. Labeling information summarized through Lantheus warns that the injection adds to cumulative radiation exposure, advises avoiding CYP1A2 inducers including tobacco for seven days before dosing, and advises nursing patients to pump and discard milk for four hours after, according to the Lantheus prescribing-information summary. Bring a full medicine list, tobacco history, pregnancy or nursing status, and prior imaging dates.
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Questions Primary Care Patients Can Bring to a Clinician
- Home-Based Dementia Care Research Priorities in 2026: What Spouses and Partners Can Check in Their Community
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: What the News Means for Family Caregivers
